Literature DB >> 11509944

Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region.

L K Hawkins1, T Hermiston.   

Abstract

Successful therapies for cancer need to deal with the complexity associated with the human tumor. Studies of tumor and viral biology have progressed to a point where replicating viruses are now being engineered as potential treatments for human cancers. The complex nature of human cancers dictates that successful treatments will require combination therapies. To this end, we have focused on developing the gene delivery capacity of the replicating adenovirus, using the non-essential E3 region transcription unit as a target site for therapeutic transgene insertions. Utilizing the endogenous expression machinery of the E3 region (promoter, splicing, polyA) we show that a therapeutic transgene, TNF, is efficiently expressed from the E3B region and with exclusive late gene expression kinetics. Potential clinical applications are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509944     DOI: 10.1038/sj.gt.3301509

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  13 in total

1.  Enhanced cytotoxicity without internuclear spread of adenovirus upon cell fusion by measles virus glycoproteins.

Authors:  German P Horn; Sompong Vongpunsawad; Evelyn Kornmann; Barbara Fritz; Dirk P Dittmer; Roberto Cattaneo; Matthias Dobbelstein
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

2.  Homologous recombination in E3 genes of human adenovirus species D.

Authors:  Gurdeep Singh; Christopher M Robinson; Shoaleh Dehghan; Morris S Jones; David W Dyer; Donald Seto; James Chodosh
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

3.  Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.

Authors:  Mingzhu Zhu; J Andrew Bristol; Yuefeng Xie; Mervat Mina; Hong Ji; Suzanne Forry-Schaudies; David L Ennist
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Core labeling of adenovirus with EGFP.

Authors:  Long P Le; Helen N Le; Amy R Nelson; David A Matthews; Masato Yamamoto; David T Curiel
Journal:  Virology       Date:  2006-05-06       Impact factor: 3.616

5.  Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy.

Authors:  T Cherry; S L Longo; Z Tovar-Spinoza; D E Post
Journal:  Gene Ther       Date:  2010-07-22       Impact factor: 5.250

6.  Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors.

Authors:  Michael Robinson; Betty Li; Ying Ge; Derek Ko; Satya Yendluri; Thomas Harding; Melinda VanRoey; Katherine R Spindler; Karin Jooss
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

Review 7.  Armed replicating adenoviruses for cancer virotherapy.

Authors:  J J Cody; J T Douglas
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

8.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01

9.  Increasing the efficacy of oncolytic adenovirus vectors.

Authors:  Karoly Toth; William S M Wold
Journal:  Viruses       Date:  2010-08-27       Impact factor: 5.818

10.  Oncolytic viruses: the power of directed evolution.

Authors:  Maxine Bauzon; Terry W Hermiston
Journal:  Adv Virol       Date:  2011-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.